Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group

NCT00146289 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00146289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
Not reported
Enrollment
138
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

insulin resistance, obesity